Kinase dysfunction and kinase inhibitors

Veterinary Dermatology

Volumn 24, Issue 1, 2013, Pages

  London, Cheryl A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ANIMAL; ARTICLE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

ANIMALIA; CANIS FAMILIARIS;

EID: 84872725217     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2012.01081.x     Document Type: Article

References (105)

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134.
2. Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004; 37: 618-635.
3. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002; 8: 17-23.
4. Barreca A, Lasorsa E, Riera L et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011; 47: R11-R23.
5. Fletcher JA. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin Oncol 2004; 31: 4-11.
6. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004; 30: 1-17.
7. Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-1488.
8. Ma PC, Maulik G, Christensen J et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-325.
9. Thurston G, Gale NW. Vascular endothelial growth factor and other signaling pathways in developmental and pathologic angiogenesis. Int J Hematol 2004; 80: 7-20.
10. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90: 1-7.
11. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 2000; 79: 1-38.
12. McCarty MF, Liu W, Fan F et al. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 2003; 9: 53-58.
13. Thurston G. Role of angiopoietins and tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003; 314: 61-68.
14. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
15. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
17. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
18. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653: 25-40.
19. Fresno Vara JA, Casado E, de Castro J et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
20. Franke TF, Hornik CP, Segev L et al. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-8998.
21. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004; 4: 235-256.
22. Markman B, Atzori F, Pérez-García J et al. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010; 21: 683-691.
23. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001; 264: 29-41.
24. Weng LP, Smith WM, Dahia PL et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 1999; 59: 5808-5814.
25. Kanae Y, Endoh D, Yokota H et al. Expression of the PTEN tumor suppressor gene in malignant mammary gland tumors of dogs. Am J Vet Res 2006; 67: 127-133.
26. Koenig A, Bianco SR, Fosmire S et al. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 2002; 39: 458-472.
27. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002; 39: 372-378.
28. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004; 5: 27-36.
29. Ortega S, Malumbres M, Barbacid M. CyclinD-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602: 73-87.
30. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-231.
31. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
32. Malumbres M, Barbacid M. RAS oncogenes: the first 30years. Nat Rev Cancer 2003; 3: 459-465.
33. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
34. Dhillon AS, Kolch W. Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 2004; 5: 303-304.
35. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55: 1-95.
36. Downing S, Chien MB, Kass PH et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002; 63: 1718-1723.
37. London CA, Galli SJ, Yuuki T et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999; 27: 689-697.
38. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002; 39: 529-535.
39. Demetri GD. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am 2002; 16: 1115-1124.
40. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011; 38(Suppl 1): S10-S19.
41. Frost D, Lasota J, Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol 2003; 40: 42-54.
42. Kondo M, Horibe K, Takahashi Y et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999; 33: 525-529.
43. Nakoa M, Yokota S, Iwai T et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
44. Yokota S, Kiyoi H, Nakao M et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-1609.
45. Iwai T, Yokota S, Nakao M et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 1999; 13: 38-43.
46. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
47. Wen J, Fu J, Zhang W et al. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod Pathol 2011; 24: 932-943.
48. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-112.
49. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
50. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2003; 132-152.
51. Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004; 28(Suppl 1): S21-S28.
52. Medves S, Demoulin JB. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med 2012; 16: 237-248.
53. Sciacca L, Costantino A, Pandini G et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999; 18: 2471-2479.
54. Ekstrand AJ, James CD, Cavenee WK et al. Genes for epidermal growth factor receptor, transforming growth factorα, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991; 51: 2164-2172.
55. Graeven U, Fiedler W, Karpinski S et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol 1999; 125: 621-629.
56. Fosmire SP, Dickerson EB, Scott AM et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 2004; 84: 562-572.
57. MacEwen EG, Kutzke J, Carew J et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 2003; 20: 421-430.
58. Ferracini R, Angelini P, Cagliero E et al. MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 2000; 18: 253-256.
59. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302.
60. Vogel CL, Cobleigh MA, Tripathy D et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61(Suppl 2): 37-42.
61. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
62. Arteaga CL, Sliwkowski MX, Osborne CK et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32.
63. Mukai H. Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol 2010; 15: 335-340.
64. Cabanillas F. Front-line management of diffuse large Bcell lymphoma. Curr Opin Oncol 2010; 22: 642-645.
65. Vidal L, Gafter-Gvili A, Salles G et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103: 1799-1806.
66. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011; 11: 777-792.
67. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
68. de Kogel CE, Schellens JH. Imatinib. Oncologist 2007; 12: 1390-1394.
69. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001; 6: 233-238.
70. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
71. Beham-Schmid C, Apfelbeck U, Sill H et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002; 99: 381-383.
72. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
73. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
74. Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev 2002; 12: 111-115.
75. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003; 6: 231-238.
76. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35-43.
77. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology 2003; 65: 187-197.
78. Heinrich MC, Rubin BP, Longley BJ et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-495.
79. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213-1220.
80. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours. Ann Chir Gynaecol 1998; 87: 278-281.
81. Peled N, Yoshida K, Wynes MW et al. Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Ther Adv Med Oncol 2009; 1: 137-144.
82. Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol 2011; 3: 279-291.
83. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
84. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
85. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget 2010; 1: 530-543.
86. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10: 395-403.
87. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009; 23: 377-389.
88. London CA, Hannah AL, Zadovoskaya R et al. PhaseI dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003; 9: 2755-2768.
89. London CA, Malpas PB, Wood-Follis SL et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009; 15: 3856-3865.
90. ®) in solid tumours(*). Vet Comp Oncol 2012; 10: 194-205.
91. Chon E, McCartan L, Kubicek LN et al. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phaseI dose-finding study(*). Vet Comp Oncol 2012; 10: 184-193.
92. Robat C, London C, Bunting L et al. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phaseI dose-finding study(*). Vet Comp Oncol 2012; 10: 174-183.
93. Carlsten KS, London CA, Haney S et al. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. J Vet Intern Med 2012; 26: 135-141.
94. Hahn KA, Ogilvie G, Rusk T et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22: 1301-1309.
95. Hahn KA, Legendre AM, Shaw NG et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res 2010; 71: 1354-1361.
96. Isotani M, Ishida N, Tominaga M et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 2008; 4: 985-988.
97. Marconato L, Bettini G, Giacoboni C et al. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med 2008; 4: 1001-1007.
98. Yamada O, Kobayashi M, Sugisaki O et al. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Vet Immunol Immunopathol 2011; 142: 101-106.
99. Isotani M, Tamura K, Yagihara H et al. Identification of a c-kit exon8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol 2006; 114: 168-172.
100. Isotani M, Yamada O, Lachowicz JL et al. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br J Haematol 2009; 148: 144-153.
101. Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 2012; 83: 1041-1048.
102. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-2249.
103. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. Clin Lymphoma Myeloma 2007; 7(Suppl 3): S120-S130.
104. Mahon FX, Deininger MW, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
105. Kosaka T, Yamaki E, Mogi A et al. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011; 2011: 165214.